CCR4 and primary cutaneous T-cell non-Hodgkin lymphoma: Use of mogamulizumab (anti-CCR4) in patients with cutaneous T cell lymphoma or solid tumors, reduced the levels of circulating or intratumoral CCR4+ Tregs, respectively, but did not induce potent antitumor effects (27, 28).